Skip to main content

OTCMKTS:UCBJF - UCB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$98.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New UCB Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UCBJF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UCBJF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for UCB in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $98.00.

Buy

The current consensus among 3 contributing investment analysts is to buy stock in UCB. This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/31/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
6/16/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
6/15/2020BarclaysReiterated RatingOverweight
i
3/5/2020BarclaysReiterated RatingOverweight
i
10/16/2019CitigroupUpgradeNeutral ➝ Buy
i
9/11/2018Jefferies Financial GroupUpgradeUnderperform ➝ Hold
i
(Data available from 5/9/2016 forward)
UCB logo
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.
Read More

Today's Range

Now: $98.00
$98.00
$98.00

50 Day Range

MA: $96.67
$94.63
$98.00

52 Week Range

Now: $98.00
$86.35
$131.00

Volume

20 shs

Average Volume

412 shs

Market Capitalization

$19.06 billion

P/E Ratio

16.84

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of UCB?

The following sell-side analysts have issued reports on UCB in the last twelve months: Barclays PLC, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for UCBJF.

What is the current price target for UCB?

0 Wall Street analysts have set twelve-month price targets for UCB in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for UCB in the next year.
View the latest price targets for UCBJF.

What is the current consensus analyst rating for UCB?

UCB currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UCBJF will outperform the market and that investors should add to their positions of UCB.
View the latest ratings for UCBJF.

What other companies compete with UCB?

How do I contact UCB's investor relations team?

UCB's physical mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company's listed phone number is 32-2559-9999 and its investor relations email address is [email protected] The official website for UCB is www.ucb.com.